This document should contain, at minimum: HPLC purity analysis showing purity percentage (look for 98% or higher, preferably 99%+) Mass spectrometry data confirming molecular identity matches retatrutide (molecular weight approximately 4,113 Da) Amino acid analysis verifying the correct 39-amino-acid sequence Residual solvent testing showing levels below ICH guidelines Water content by Karl Fischer analysis (typically below 5%) Peptide content showing actual peptide mass versus total vial contents A COA missing any of these core analyses should raise immediate concerns
Biochemical and Biophysical Research Communications 736:150892 Tsai CC, Wang PC, Hsiung T, Fan YH, Wu JT, Kan WC, Shiao CC (2025) sarcopenia in chronic kidney disease: A narrative review from pathophysiology to therapeutic approaches
Retatrutide shows higher discontinuation rates
These drugswhen combined with a healthy diet and exercisecan help you lose weight and feel amazing just in time for the sunny season
The following is one example of a titration schedule used in Phase 2 protocols it does not represent a single universal regimen, and other escalation speeds were also evaluated: Weeks 14: 2 mg once weekly (initiation dose) Weeks 58: 4 mg once weekly Weeks 912: 8 mg once weekly Week 13 onwards: 12 mg once weekly (where tolerated) This gradual up-titration mirrors the approach used with approved agents such as semaglutide and tirzepatide, where slow dose escalation is essential to improve gastrointestinal tolerability
